Ukr.Biochem.J. 2021; Volume 93, Issue 5, Sep-Oct, pp. 117-121


Osteoprotegerin, sclerostin, and osteocalcin serum levels in thyroid disorder patients

F. F. Rija1, S. Z. Hussein2*, M. A. Abdalla3

1Department of Biology, Tikrit University – College of Sciences, Tikrit, Iraq;
2Clinical Biochemistry Unit, Salah Aldeen Health Directorate, Tikrit, Iraq;
3Department of Human Anatomy, Tikrit University College of Medicine, Tikrit, Iraq;

Received: 15 February 2021; Accepted: 22 September 2021

The maintenance of thyroid hormone homeostasis is essential in the regulation of skeletal system development, bone tissue mineralization and fracture risk prevention. This study was carried out to evaluate the serum level of osteoprotegerin (OPG), sclerostin (SOST), and osteocalcin (OC) in hypo- and hyperthyroidism patients. A total number of examined patients was 90 individuals, 30 of them were normal as a control group, the rest 60 individuals were arranged in two groups: 30 patients with hypothyroidism and 30 patients with hyperthyroidism. Serum assay tests for OPG, SOST, OC, thyroid stimulating hormone (TSH), total triiodothyronine (T3), and total thyroxine (T4) were used. The present study reported high levels of SOST, T3, and T4 and low levels of OPG, OC, and TSH in patients with  hyperthyroidism compared to control. Whereas in patients with hypothyroidism only SOST and TSH levels were increased, but OPG, OC, T3, and T4 levels were low compared to control. The data obtained indicate the correlation on osteoprotegerin, sclerostin, and osteocalcin levels with thyroid hormones disturbances.

Keywords: , , ,


  1. Gogakos AI , Duncan Bassett JH, Williams GR. Thyroid and bone. Arch Biochem Biophys. 2010;503(1):129-136. PubMed,CrossRef
  2. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002;23(1):38-89. PubMed, CrossRef
  3. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M. TSH is a negative regulator of skeletal remodeling. Cell. 2003;115(2):151-162. PubMed, CrossRef
  4. Hussein SZ, Ali SJ. Evaluation of Serum Thyroid Hormones and Cortisol Level in Patients with Chronic Renal Failure. 1st scientific conference of medical group colleges 26-27 March 2013; 32-37.
  5. Hussein SZ, Farhan AS. Ferritin Level in Thyroid Diseases. 1st scientific conference of medical group colleges 26-27 March 2013; 21-25.
  6. Davies TF, Ando T, Lin RY, Tomer Y, Latif R. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest. 2005;115(8):1972-1983. PubMed, PubMedCentral, CrossRef
  7. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res. 2009;24(10):1651-1661. PubMed, CrossRef
  8. Sarıtekin İ, Açıkgöz Ş, Bayraktaroğlu T, Kuzu F, Can M, Güven B, Mungan G, Büyükuysal Ç, Sarıkaya S. Sclerostin and bone metabolism markers in hyperthyroidism before treatment and interrelations between them. Acta Biochim Pol. 2017;64(4):597-602. PubMed, CrossRef
  9. Rija FF, Almahdawi ZM, Hussein SZ. Evaluation of Bone Metabolism Biomarkers in Hemodialysis Chronic Kidney Disease. Indian J Public Health Res Dev. 2019; 10(4): 1660-1665. CrossRef
  10. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med (Berl). 2001;79(5-6):243-253. PubMed, CrossRef
  11. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res. 2001;16(2):348-360. PubMed, CrossRef
  12. Amato G, Mazziotti G, Sorvillo F, Piscopo M, Lalli E, Biondi B, Iorio S, Molinari A, Giustina A, Carella C. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone. 2004;35(3):785-791. PubMed, CrossRef
  13. Zhong N, Xu B, Cui R, Xu M, Su J, Zhang Z, Liu Y, Li L, Sheng C, Sheng H, Qu S. Positive Correlation between Serum Osteocalcin and Testosterone in Male Hyperthyroidism Patients with High Bone Turnover. Exp Clin Endocrinol Diabetes. 2016;124(7):452-456. PubMed, CrossRef
  14. Rija FF, Almahdawi ZM, Hussein SZ. Correlation between Calcium Sensing Receptor with other Calcium Regulators in Osteoporosis and Osteomalacia Patients. Plant Arch. 2019; 19(1): 1199-1207.
  15. O’Shea PJ, Kim DW, Logan JG, Davis S, Walker RL, Meltzer PS, Cheng SY, Williams GR. Advanced bone formation in mice with a dominant-negative mutation in the thyroid hormone receptor β gene due to activation of Wnt/β-catenin protein signaling. J Biol Chem. 2012;287(21):17812-17822.
    PubMed, PubMedCentral, CrossRef
  16. Tsourdi E, Rijntjes E, Köhrle J, Hofbauer LC, Rauner M. Hyperthyroidism and Hypothyroidism in Male Mice and Their Effects on Bone Mass, Bone Turnover, and the Wnt Inhibitors Sclerostin and Dickkopf-1. Endocrinology. 2015;156(10):3517-3527. PubMed, CrossRef
  17. Wang L, Shao YY, Ballock RT. Thyroid hormone interacts with the Wnt/beta-catenin signaling pathway in the terminal differentiation of growth plate chondrocytes. J Bone Miner Res. 2007;22(12):1988-1995. PubMed, CrossRef
  18. Lee AJ, Hodges S, Eastell R. Measurement of osteocalcin. Ann Clin Biochem. 2000;37(Pt 4):432-446. PubMed, CrossRef
  19. Heymann MF, Riet A, Le Goff B, Battaglia S, Paineau J, Heymann D. OPG, RANK and RANK ligand expression in thyroid lesions. Regul Pept. 2008;148(1-3):46-53. PubMed, CrossRef
  20. Rija FF, Hussein SZ, Abdalla MA. Physiological and Immunological Disturbance in Rheumatoid Arthritis Patients. Baghdad Sci J. 2021;18(2):247-252.

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.